Budget Amount *help |
¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2011: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
Research Abstract |
Administration of incretin (human GLP-1 analog) with or withoutCFA improved diabetes in newly diabetic NOD mice, but not in newly diabetic NODRhebmice (R3 lines), which accelerate diabetes progression. Newly diabetic NODRhebmice represented no induction of Treg into pancreatic islets and no islet regeneration. In addition, NODRhebmice showed more increased diabetes onset than NOD mice during the perinatal period and more decreased delivery. NODRhebmice also showed more accelerated diabetes progression than NOD mice after delivery.
|